CRISPR Therapeutics AG (CRSP) Accounts Payables (2015 - 2026)

CRISPR Therapeutics AG has disclosed Accounts Payables across 12 years of filings, most recently posting $11.3 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 15.93% year-over-year to $11.3 million; the TTM figure through Jun 2026 stood at $11.3 million (up 15.93% YoY), while the FY2025 annual figure was $11.1 million, down 24.28% from the prior year.
• Accounts Payables came in at $11.3 million for Q2 2026 at CRISPR Therapeutics AG, down from $13.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $45.2 million in Q1 2023 to a low of $9.5 million in Q2 2024.
• Average Accounts Payables over 5 years is $20.9 million, with a median of $16.0 million recorded in 2024.
• Year-over-year, Accounts Payables soared 215.87% in 2022 and tumbled 65.74% in 2024.
• Over 5 years, Accounts Payables stood at $27.4 million in 2022, then jumped by 39.08% to $38.1 million in 2023, then slumped by 61.44% to $14.7 million in 2024, then slipped by 24.28% to $11.1 million in 2025, then advanced by 1.52% to $11.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $11.3 million in Q2 2026, $13.6 million in Q1 2026, and $11.1 million in Q4 2025.